Miebo access in Jordan: the JFDA named-patient pathway
How patients in the Hashemite Kingdom of Jordan legally obtain Miebo (perfluorohexyloctane ophthalmic solution) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Jordan access Miebo (perfluorohexyloctane ophthalmic solution) for signs and symptoms of dry eye disease, including evaporative dry eye associated with meibomian gland dysfunction through the JFDA named-patient pathway, a Jordan Food and Drug Administration-administered mechanism that allows a Jordanian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in JOD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Jordanian patients need Miebo through the named-patient pathway
The Hashemite Kingdom of Jordan operates a structured pharmaceutical regulatory environment. Miebo (perfluorohexyloctane ophthalmic solution) is regulated through JFDA (Jordan Food and Drug Administration) channels, and a Jordanian family asking for Miebo is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Miebo's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. MedNet Jordan, GlobeMed Jordan, and Newton Insurance each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Jordan or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the JFDA named-patient pathway is the mechanism that connects a Jordanian-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Miebo is a semifluorinated alkane eye drop that forms a stable monolayer at the tear-film air interface to slow tear evaporation, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Miebo in Jordan
Miebo (perfluorohexyloctane ophthalmic solution; Bausch + Lomb / Novaliq) is a semifluorinated-alkane preservative-free eye drop for the signs and symptoms of dry eye disease including evaporative dry eye associated with meibomian gland dysfunction. The mechanism (a thin monolayer at the tear-film air interface that retards tear evaporation) is distinct from secretagogue, immunomodulator, or anti-inflammatory dry-eye products.
As of 2026-05-31, no public JFDA record of a Jordan marketing authorisation for perfluorohexyloctane has been observed. Bausch + Lomb maintains a regional ophthalmology distributor footprint in Jordan; whether Miebo has been notified for regional registration depends on the licensing partner's commercial plan.
Where Miebo is not locally registered, access proceeds under Article 34 of the Drug and Pharmacy Law No. 12 of 2013 as a personal-importation file. Because dry-eye disease is a chronic outpatient indication, the file customarily requests a three-month supply (one 3 mL bottle per month is the FDA-labelled cadence) renewable by subsequent permit.
Last verified by ARCH-74: 2026-05-31. Quarterly JFDA bulletin scan picks up class-level ophthalmic safety updates if gazetted.
Named tertiary centres in Jordan where Miebo is dispensed
Miebo is an outpatient ophthalmic-clinic product; in Jordan the relevant centres are:
- Jordan University Hospital, Amman - Department of Ophthalmology with cornea, dry-eye, and meibomian-gland-dysfunction sub-clinics.
- King Abdullah University Hospital, Irbid - Department of Ophthalmology; northern Jordan academic tertiary ophthalmology service.
- Royal Medical Services - King Hussein Medical Center, Amman - Department of Ophthalmology.
- Istishari Hospital, Amman - private tertiary multi-specialty with ophthalmology service.
- Specialty Hospital, Amman - private tertiary multi-specialty with cornea and ocular-surface clinic.
Jordan has a dedicated National Center for Diabetes, Endocrinology and Genetics (NCDEG) that handles diabetes-associated dry-eye complications via referral to the above tertiary ophthalmology centres. Specialty dry-eye clinics often coordinate with rheumatology (Sjögren-syndrome) and ENT (lacrimal-system) services depending on the underlying aetiology.
Local pricing reference for Miebo in Jordan
US WAC reference for Miebo (perfluorohexyloctane ophthalmic solution, 3 mL bottle) is in the order of USD 300 to USD 400 per 30-day supply at the FDA-labelled four-times-daily dosing schedule. Source: Miebo FDA Prescribing Information.
No public JOD reference price for perfluorohexyloctane has been observed on JFDA, the MOH controlled-medicine list, or major-importer published lists as of 2026-05-31. JOD is pegged to USD at approximately 0.71 JOD per USD; for indicative reference the 30-day USD band translates to approximately JOD 213 to JOD 284, although the actual JOD figure depends on JFDA permit fee, importer margin, and dispensing pharmacy overhead.
Price snapshot date: 2026-05-31. The product is ambient-storage; cold-chain overhead is not part of the quotation. Concomitant dry-eye therapies (preservative-free artificial tears, cyclosporine ophthalmic emulsion, lifitegrast) are locally available and are separate cost lines outside this import file.
Country-specific access barriers for Miebo in Jordan
The principal access barrier for Miebo in Jordan is the chronic outpatient dosing schedule. Patients dose four times daily and use approximately one 3 mL bottle per month. Each JFDA permit covers a defined supply period (commonly three months); chronic-therapy patients re-apply per cycle, and the recurring administrative cost is material relative to the modest per-month drug cost.
Public-sector funding posture for novel dry-eye therapies in Jordan is constrained. The Ministry of Health and Royal Medical Services formularies cover preservative-free artificial tears, cyclosporine ophthalmic emulsion, and corticosteroid eye drops for short-course use; novel semifluorinated-alkane therapies are not on the formulary as of 2026-05-31. Source: MOH Jordan. For patients in the public-sector channel, the ophthalmologist typically tries the formulary-listed options first before initiating a cross-border Miebo file.
Private-insurance coverage of ophthalmic specialty drops is policy-specific. Group-corporate plans (MetLife Jordan, Arab Orient Insurance, Jordan Insurance Company) cover dry-eye therapy in chronic-condition riders, but novel-mechanism preservative-free products may require pre-authorisation. Refugee-population context (Syrian, Palestinian, Iraqi) is material; UNHCR-supported procurement covers refractive-error and basic-ophthalmic-care needs but does not customarily extend to novel dry-eye therapies.
Because the per-unit cost is modest and the file is straightforward (ambient-storage ophthalmic solution, no controlled-substance designation), customs clearance and dispensing-pharmacy overhead represent a meaningful share of the total quoted cost; the operational efficiency of permit batching at the dispensing hospital is the practical lever.
Recent local regulatory news touching Miebo or its drug class in Jordan
No JFDA bulletin specifically naming perfluorohexyloctane or the semifluorinated-alkane ophthalmic class has been observed in the last twelve months on the JFDA Recalls and Safety Communications page as of 2026-05-31. Adjacent context:
- FDA labelling iteration on Miebo since the initial 2023 approval has primarily concerned post-marketing safety updates; no class-specific regional regulator restriction has been gazetted by JFDA. Source: FDA Drugs@FDA database.
- JFDA Drug Directorate's ongoing digital-permit-submission rollout is relevant operationally for the chronic-cycle ophthalmic file pattern. Source: JFDA.
What your physician needs to provide
For a Jordanian-licensed specialist prescribing Miebo through the JFDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for signs and symptoms of dry eye disease, including evaporative dry eye associated with meibomian gland dysfunction, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Miebo is the appropriate next step given a semifluorinated alkane eye drop that forms a stable monolayer at the tear-film air interface to slow tear evaporation.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Miebo (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Jordanian license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Miebo in Jordan
Will MedNet Jordan, GlobeMed Jordan, and Newton Insurance cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Miebo is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by JFDA? The JFDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; JFDA review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Jordanian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Jordan Medical Council and the JFDA verifies the active license; the JFDA application records both the prescribing physician and the dispensing facility.
Can I receive Miebo at home? The dispensing facility must be Jordanian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Miebo cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace JFDA, and we do not replace your dispensing pharmacy. For Miebo specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Jordan, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Miebo case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the JFDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Jordanian tertiary specialty care concentrates at KHCC, Jordan University Hospital, and Istishari Hospital in Amman, with King Abdullah University Hospital in Irbid serving as the principal academic referral centre in the north; the JFDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines.
Next step
If your Jordanian physician has prescribed Miebo and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.